Clinical Trial Update: Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis

View source ↗

Summary

The update discusses mutations in K-RAS, CDKN2A, SMAD4, and TP53 in pancreatic cancer and evaluates liquid biopsy for preoperative diagnosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: University of Roma La Sapienza | Conditions: Pancreatic Cancer | Status: UNKNOWN